8:00am-10:15am

PLENARY SESSION 1 -
Therapy Response, Plasticity and Resistance

Salon A-F
Session Chair: Andrew Aplin

Session available virtually

8:00am - 8:20am

Evolution of metastases and therapy resistance in melanoma

Click here to view this session

Samra Turajlic

8:20am - 8:35am

Defining the persister cancer cell state after melanoma therapy shows the unfolded protein response as conferring resistance

Click here to view this session

Maggie Chasse

8:35am - 8:50am

H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase in melanoma

Click here to view this session

 Helmut Schaider

8:50am - 9:10am

Interleukin 17 signaling supports clinical benefit of dual immune checkpoint inhibition in melanoma

Click here to view this session

Alex Roesch

9:10am - 9:25am

ZEB1-dependent melanoma cell plasticity supports immune evasion and patients’ resistance to immunotherapy by shaping the immune microenvironment

Click here to view this session

Anaïs Eberhardt

9:25am - 9:40am

Metabolic rewiring to improve melanoma tumor responses to both targeted and immunotherapies.

Click here to view this session

Imanol  Arozarena

9:40am - 9:55am

Targeting the CoREST Complex Promotes Immunogenic and Tumor Suppressive RNA Splicing

Click here to view this session

Robert Fisher

9:55am - 10:15am

Role of PD-1hiFoxp3-CD4+ tumor-infiltrating lymphocytes in anti-tumor immunity

Click here to view this session

Roberta Zappasodi

10:45am - 11:05am

Novel mechanisms of melanoma adaptation to the brain microenvironment

Eva Hernando, Recipient of the 2023 Estela Medrano Award

11:05am - 11:20am

Combined Inhibition of RAF, MEK, and FAK Attenuates Melanoma Brain Metastases and Improves Overall Survival in Preclinical Models

Jared Almazan

11:20am - 11:35am

Spatially Mapping the Melanoma Immune Landscape of Brain Metastases using Imaging Mass Cytometry

Jamie Magrill

11:35am - 11:50am

Spatial multi-omic analysis identifies a unique pro-tumorigenic function of the meningeal stroma in melanoma leptomeningeal disease

Inna Smalley

11:50am - 12:05pm

Targeting Brain Macrophages to Block Melanoma Brain Metastases and Improve Responses to Immunotherapies

Berta Sanchez-Laorden

12:05pm - 12:25pm

Dissecting brain metastasis ecosystems at single-cell resolution

Ben Izar

10:45am - 11:05am

The role of tumor-host interactions in mucosal melanoma anti-tumor immunity

Kasey Couts

11:05am - 11:20am

Lineage commitment pathways epigenetically oppose oncogenic Gaq-YAP1/TEAD signaling to drive dormancy of uveal melanoma

Rama Kadamb

11:20am - 11:35am

The Mechanically Distinct Foot Tumor Microenvironment Drives Acral Lentiginous Melanoma Proliferation, Invasion, and Therapy Resistance

Bailey Robertson

11:35am - 11:55am

Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study

Harriett Kluger

11:55am - 12:10pm

Single-cell elucidation of the immune microenvironment and its association with canonical genetic aberrations in uveal melanoma

J. William Harbour

12:10pm - 12:30pm

Targeting Signaling Vulnerabilities in Uveal Melanoma: New Multimodal Precision Therapies

Silvio Gutkind

2:00pm - 2:20pm

Modeling human melanoma to develop new targeted and immune therapies

Click here to view this session

Meenhard Herlyn, SMR Founding Member

2:20pm - 2:35pm

Gut microbial proteins predict adverse events and immune responses in melanoma

Click here to view this session

Noam Auslander

2:35pm - 2:50pm

It’s All About the Data: International Melanoma Database and Discovery Platform (IMDDP) Quality Assurance (QA) Initiative

Click here to view this session

Jeffrey Gershenwald

2:50pm - 3:05pm

Development of a melanocyte lineage-specific knockout system in zebrafish

Click here to view this session

Sarah Perlee

3:05pm - 3:20pm

The SWI/SNF remodeler PBAF facilitates REST occupancy at inactive chromatin in the melanocytic lineage

Click here to view this session

Elena Grossi

3:20pm - 3:40pm

Mouse models for melanoma biology

Click here to view this session

Florian Karreth

4:00pm - 4:20pm

Direct Pharmacological Targeting of NRAS Oncoproteins for Future Melanoma Therapy

Martin McMahon

4:20pm - 4:35pm

Conformation selectivity of MAPK-targeting inhibitors determines tumor-selective potency in RAS-Mutant melanomas

Poulikos Poulikakos

4:35pm - 4:50pm

Genetic silencing of AKT induces melanoma cell death via mTOR suppression

Gennie Parkman

4:50pm - 5:05pm

Novel therapeutic strategy to prevent metastasis by inducing dormancy of melanoma cells

Maria Sosa

5:05pm - 5:20pm

Co-option of insulin signaling confers liver-metastatic organotropism

Meri Rogava

5:20pm - 5:40pm

Invited Presentation 

Jessie Villanueva

4:00pm - 4:20pm

Neoadjuvant Therapy in Clinical Stage III Melanoma

Rodabe Amaria

4:20pm - 4:35pm

Development and Validation of Time-to-Event Models to Predict Metastatic Recurrence of Localized Cutaneous Melanoma

Yevgeniy Semenov

4:35pm - 4:50pm

mRNA-4157/V940, an individual neoantigen therapy, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy, safety, and translational results from the randomized, open- label Phase 2 mRNA-4157-P201

 Jeffrey Weber

4:50pm - 5:05pm

Adjuvant nivolumab (NIVO) v placebo (PBO) in stage IIB/C melanoma: longer follow-up from CheckMate 76K

John Kirkwood

5:05pm - 5:25pm

Open questions and next steps for adjuvant therapy of high-risk early-stage melanoma

Jason Luke